Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.